🔎 Trials Near Me

መነሻ › ትሪፕል-ኔጌቲቭ የደረት ካንሰር › ጆርጂያ

በጆርጂያ ለትሪፕል-ኔጌቲቭ የደረት ካንሰር የሚደረጉ ክሊኒካዊ ጥናቶች

ለትሪፕል-ኔጌቲቭ የደረት ካንሰር የሚደረጉ 26 ጥናቶች በጆርጂያ ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።

በጆርጂያ ውስጥ ያሉ ከተሞች

Official study text (English)

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

  • Winship Cancer Institute of Emory University, Atlanta
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT06270706

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

  • Emory University, Atlanta
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT06465069

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

  • Emory Winship Cancer Institute, Atlanta
  • Augusta University, Augusta
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 19 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ1 ኦክቶ 2026 · NCT06586957

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

  • University Cancer & Blood Center, LLC ( Site 0023), Athens
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT06841354

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

  • City of Hope Cancer Center - Atlanta ( Site 0102), Newnan
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT06966700

A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer

  • Emory University (Data Collection Only), Atlanta
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ9 ሴፕቴ 2026 · NCT05570253

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

  • University Cancer & Blood Center, LLC., Athens
  • Piedmont Cancer Institute, Atlanta
  • Northside Hospital, Atlanta
  • እና 3 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ9 ሴፕቴ 2026 · NCT05633654

A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

  • Emory University, Atlanta
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ4 ሴፕቴ 2026 · NCT06400472

Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers

  • Emory University, Atlanta
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ3 ሴፕቴ 2026 · NCT05846789

ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

  • Emory University Winship Cancer Institute, Atlanta
  • Winship Cancer Institute of Emory University, Atlanta
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ31 ኦገስ 2026 · NCT06460298

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

  • Northside Hospital, Atlanta
ተሳታዮችን በመፈለግ ላይደረጃ 2/3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ10 ኦገስ 2026 · NCT06926868

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

  • Augusta University Georgia Cancer Center, Augusta
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ4 ኦገስ 2026 · NCT05579366

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

  • University Cancer & Blood Center, Athens
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ጁላይ 2026 · NCT06150664

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

  • Winship Cancer Institute, Emory University, Atlanta
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ29 ጁን 2026 · NCT05377996

Study of XB010 in Subjects With Solid Tumors

  • Winship Cancer Institute, Atlanta
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ጁን 2026 · NCT06545331

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

  • Winship Cancer Institute / Emory University, Atlanta
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ15 ጁን 2026 · NCT05768932

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

  • Georgia Cancer Center, Augusta
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ4 ጁን 2026 · NCT04300556

Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer

  • Emory University Hospital, Atlanta
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሴቶች · የተሻሻለው በ4 ጁን 2026 · NCT05741164

Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab

  • Emory University/Winship Cancer Institute, Atlanta
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናትጤናማ ተሳታዮች ይቀበላሉ
እድሜ 18 እና ከዚያ በላይ · ሴቶች · የተሻሻለው በ7 ሜይ 2026 · NCT05877859

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

  • Winship Cancer Institute of Emory University, Atlanta
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ6 ሜይ 2026 · NCT01042379

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

  • Emory University Hospital/Winship Cancer Institute, Atlanta
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ17 ኤፕሪ 2026 · NCT06492759

Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer

  • Emory University, Winship Cancer Institute, Atlanta
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ፌብሩ 2026 · NCT02926690

A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

  • Winship Cancer Institute - Emory University, Atlanta
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ30 ጃንዩ 2026 · NCT06926920

Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

  • Grady Health System, Atlanta
  • Emory University Hospital Midtown, Atlanta
  • Emory University Hospital/Winship Cancer Institute, Atlanta
  • እና 1 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ26 ጃንዩ 2026 · NCT06324240

A Beta-only IL-2 ImmunoTherapY Study

  • Emory - Winship Cancer Institute, Atlanta
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ9 ጁላይ 2025 · NCT05086692

A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients

  • Columbus Regional Research Institute, LLC, Columbus
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ18 እስከ 65 · ሴቶች · የተሻሻለው በ21 ማርች 2025 · NCT03671044

ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ6 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።